Authors
Latest:
Novel Delivery Systems, Unique Pairings Explored With Oncolytic VirusesOncoloytic viruses are an emerging class of cancer therapeutics that may provide a new strategy against malignant tumors.
Latest:
Behind a Real-World Study of Lenvatinib in RAI-Refractory DTCFrancis P. Worden, MD, discusses a real-world study evaluating lenvatinib for the treatment of patients with radioiodine-refractory differentiated thyroid cancer.
Latest:
Portell on the Changing Landscape of Mantle Cell LymphomaCraig A. Portell, MD, discusses the current standard of care for patients with relapsed/refractory mantle cell lymphoma and how sequencing therapies changed the landscape of mantle cell lymphoma treatment.
Latest:
Referral for CAR T Should Always Be Considered in R/R Multiple MyelomaKenneth Shain, MD, PhD, discusses why he recommends most patients with relapsed/refractory multiple myeloma be referred for evaluation to receive chimeric antigen receptor T-cell therapy.
Latest:
Buttin Reviews Results From PAOLA-1 in Ovarian CancerBarbara Buttin, MD, discusses the PAOLA-1 clinical trial and it impact on the first-line treatment of ovarian cancer.
Latest:
Treatment Landscape for Vulvar/Vaginal MelanomaAnnelise Wilhite, MD, explains what current treatment options look like for patients with vulvar/vaginal melanoma.
Latest:
Rusfertide May Reduce Need for Therapeutic Phlebotomy in Polycythemia VeraYelena Ginzburg, MD, discusses a long-term goal of the use of rusfertide in patients with chronic polycythemia vera.
Latest:
Lutetium-PSMA-617 and Novel Agents in Prostate CancerOncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.
Latest:
Belumosudil Shows Sustained Efficacy and Safety for Chronic GVHDStephanie Lee, MD, discusses a study investigating belumosudil for chronic graft-vs-host disease.
Latest:
Final Remarks and Thank-YouTiciana Leal, MD, discusses how emerging targeted therapies for extensive-stage small cell lung cancer (ES-SCLC) are showing promising objective clinical outcomes that may surpass those of second-line treatments such as topotecan and CAV regimens, particularly highlighting the need to evaluate specific compounds based on platinum-sensitive vs platinum-resistant disease profiles and the potential role of TIGIT inhibitors in future treatment lines.
Latest:
Exploring Subgroups of Patients Likely to Refuse HSCT for Myeloma TreatmentChakra Chaulagain, MD, discusses findings from a comprehensive examination of National Cancer Database data from 2004 to 2020 regarding the utilization of autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Latest:
Future Treatments in Ovarian CancerAn expert reviews the ongoing ARIEL4 phase III trial and explains what the future of ovarian cancer treatment looks like.
Latest:
Mechanism of Action Compared With Other Alkylating AgentsJoshua K. Sabari, MD, describes the mechanism of action of lurbinectedin as a synthetic alkaloid that binds to guanine residues in the minor groove of DNA, forming adducts that disrupt DNA repair mechanisms and promote apoptosis in cancer cells, noting that its action contrasts with traditional alkylating agents by specifically interfering with DNA-protein interactions and transcription processes.
Latest:
Study Evaluates Use of Radiation Therapy in Pancreatic CancerMichael Chuong, MD, discusses the study design of a trial evaluating radiation therapy in patients with locally advanced pancreatic cancer.
Latest:
Pluvicto Approval Launches Theranostics in Prostate CancerAshok Muthukrishnan, MD, MS, addresses the recent FDA approval of lutetium 177Lu vipivotide tetraxetan and looks to the potential of radioimmunotheranostics on the horizon.
Latest:
Melanoma Monday: From Early Detection to Cutting-Edge TreatmentsMay 6, 2024, is Melanoma Monday. In this article, Niroshana Anandasabapathy, MD, PhD, explores how advancements in detection and treatment are improving the fight against melanoma.
Latest:
Promising New Regimens for Treating Acute Myeloid LeukemiaAlice S. Mims, MD, MSCR, discusses new regimens for treating patients with acute myeloid leukemia, including anti-CD47 immunotherapy, IDH inhibitors, and menin inhibitors.
Latest:
Beyond the Transplant: Long-Term Outcomes and Quality of Life in allo-HCT PatientsNeel Bhatt, MBBS, MPH, discusses a study exploring long-term quality of life outcomes of patients who underwent stem cell transplantation for aplastic anemia.
Latest:
The Ideal Patient for Biomarker Testing in Anal CarcinomaCathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.
Latest:
Future Outlooks in the Treatment of CLL/SLLFocusing on the future of CLL/SLL treatment, Mazyar Shadman, MD, MPH, discusses promising therapies in the pipeline.
Latest:
AI-Derived Biomarker Predicts Benefit of Long-Term ADT in Prostate CancerAndrew J. Armstrong, MD, ScM, discusses the methods behind a study that established a digital pathology biomarker for the benefit of androgen deprivation therapy in localized high-risk prostate cancer.
Latest:
Importance of NAPOLI 3 in Pancreatic Cancer for Community OncologistsZev A. Wainberg, MD, discusses the pressing relevance of the outcomes of the NAPOLI 3 trial, which were presented at the 2023 Gastrointestinal Cancers Symposium.
Latest:
Hillmen Analyzes Current and Upcoming Trials of BTK InhibitorsDuring a Targeted Oncology Case-Based Peer Perspectives event, Peter Hillmen, MBChB, PhD, discussed the case of 61-year-old patient with diffuse infiltration by chronic leukocytic leukemia.
Latest:
Recommendations for Treating Patients With TP53-Mutated AML or MDSMelhem Solh, MD, discusses the future for patients with myelodysplastic syndrome and acute myeloid leukemia that harbors a TP53 gene mutation, and gives his own recommendations to community oncologists who are treating patients with this disease.
Latest:
Expanding Allogeneic Stem Cell Transplantation for Relapsed and Refractory Acute Myeloid LeukemiaAllogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.
Latest:
Improved Communication Needed for Patients Living with Renal Cell CarcinomaA lack of understanding about renal cell carcinoma (RCC), clinical trials, and the diseases psychosocial impact may exist in patients living with the illness and their families.
Latest:
Enhanced Outcomes with Relatlimab, Nivolumab, and Chemotherapy in Advanced Non-Small Cell Lung CancerAdding relatlimab to nivolumab and chemotherapy improved clinical benefit in patients with stage IV non–small cell lung cancer compared to nivolumab and chemotherapy alone.
Latest:
Evolving Strategies in Hematopoietic Stem Cell Transplant ConditioningSergio A. Giralt, MD, discusses what the most commonly used conditioning regimens for patients with myelodysplastic syndrome undergoing transplants are.
Latest:
KEYNOTE-522 Trial: Pembrolizumab Boosts Survival in Early TNBCPeter Schmid, MD, PhD, discusses the background, methods, and design of the phase 3 KEYNOTE-522 trial.
